Cost-effectiveness of targeted screening for non-valvular atrial fibrillation in the United Kingdom in older patients using digital approaches

References

• Dai H, Zhang Q, Much AA, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the global burden of disease study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574–582.
   PubMed Web of Science ®Google Scholar
• Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century. Circ Res. 2020;127(1):4–20.
   PubMed Web of Science ®Google Scholar
• Sieck S. The economic impact of atrial fibrillation in the US. In: Peacock WF, Clark CL, editors. Short stay management of atrial fibrillation. Cham: Springer International Publishing; 2016. p. 27–40.
   Google Scholar
• Turakhia MP, Shafrin J, Bognar K, et al. Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States. Am J Cardiol. 2015;116(5):733–739.
   PubMed Web of Science ®Google Scholar
• Wang L, Ze F, Li J, et al. Trends of global burden of atrial fibrillation/flutter from global burden of disease study 2017. Heart. 2021;107(11):881–887.
   PubMed Web of Science ®Google Scholar
• Velleca M, Costa G, Goldstein L, et al. A review of the burden of atrial fibrillation: understanding the impact of the new millennium epidemic across Europe. EMJ Cardiol. 2019;7(1):110–118.
   Google Scholar
• Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke. 2005;36(2):360–366.
   PubMed Web of Science ®Google Scholar
• Lacoin L, Lumley M, Ridha E, et al. Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. BMJ Open. 2017;7(9):e015363.
   PubMed Web of Science ®Google Scholar
• Reiffel JA. Atrial fibrillation and stroke: epidemiology. Am J Med. 2014;127(4):e15–e16.
   PubMedGoogle Scholar
• Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes. 2022;8(2):187–194.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management [NG196]; 2021. Available from: https://www.nice.org.uk/guidance/ng196/evidence
   Google Scholar
• Foundation BH. Atrial fibrillation: finding the missing 300,000 2019. Available from: https://www.bhf.org.uk/for-professionals/healthcare-professionals/blog/2019/atrial-fibrillation-finding-the-missing-300000
   Google Scholar
• Jones NR, Taylor CJ, Hobbs FDR, et al. Screening for atrial fibrillation: a call for evidence. Eur Heart J. 2020;41(10):1075–1085.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic surgery (EACTS). Eur Heart J. 2021;42(5):373–498.
   PubMed Web of Science ®Google Scholar
• Hill NR, Ayoubkhani D, McEwan P, et al. Predicting atrial fibrillation in primary care using machine learning. PLoS One. 2019;14(11):e0224582.
   PubMed Web of Science ®Google Scholar
• Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation. 2015;131(25):2176–2184.
   PubMed Web of Science ®Google Scholar
• Lyth J, Svennberg E, Bernfort L, et al. STROKESTOP: cost-effectiveness of population screening for atrial fibrillation based on long-term follow-up data. European Society of Cardiology Congress 2021 - The Digital Experience; presented 27 August 2021.
   Google Scholar
• Welton NJ, McAleenan A, Thom HH, et al. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2017;21(29):1–236.
   Web of Science ®Google Scholar
• Hobbs FDR, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005;9(40):93.
   Web of Science ®Google Scholar
• Hill NR, Groves L, Dickerson C, et al. Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomised controlled trial in England. J Med Econ. 2022;25(1):974–983.
   PubMed Web of Science ®Google Scholar
• Szymanski T, Ashton R, Sekelj S, et al. Budget impact analysis of a machine learning algorithm to predict high risk of atrial fibrillation among primary care patients. EP Europace. 2022;24(8):1240–1247.
   PubMed Web of Science ®Google Scholar
• Oguz M, Lanitis T, Li X, et al. Cost-effectiveness of extended and one-time screening versus no screening for non-valvular atrial fibrillation in the USA. Appl Health Econ Health Policy. 2020;18(4):533–545.
   PubMed Web of Science ®Google Scholar
• British Heart Foundation Statistics. Heart & circulatory disease statistics 2020; 2020 [cited 2021 Jul 23]. Available from: https://www.bhf.org.uk/what-we-do/our-research/heart-statistics/heart-statistics-publications/cardiovascular-disease-statistics-2020
   Google Scholar
• National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management [NG196]. G2: Anticoagulant therapy: health economics analysis; 2021 [2021 Jan 14]. Available from: https://www.nice.org.uk/guidance/ng196/evidence/g2-anticoagulant-therapy-health-economics-analysis-pdf-9081923443
   Google Scholar
• Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. The Lancet. 2009;373(9665):739–745.
   Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Tawfik A, Bielecki JM, Krahn M, et al. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol. 2016;8:93–107.
   PubMedGoogle Scholar
• Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35(28):1897–1906.
   PubMed Web of Science ®Google Scholar
• Office of National Statistics. National life tables – life expectancy in the UK: 2017 to 2019 [Dataset]; 2020 [cited 2021 Jul 8]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nationallifetablesunitedkingdom/2017to2019
   Google Scholar
• Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1–11.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Resource impact template: KardiaMobile for the ambulatory detection of atrial fibrillation (MTG64); 2022 [cited 2022 Feb 21]. Available from: https://www.nice.org.uk/guidance/mtg64
   Google Scholar
• Afzal S, Zaidi STR, Merchant HA, et al. Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting. J Thromb Thrombolysis. 2021;52(2):646–653.
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee. British national formulary (online). London: BMJ Group and Pharmaceutical Press; 2021. Available from: http://www.medicinescomplete.com
   Google Scholar
• Kind P, Hardman G, Macran S. UK population norms for EQ-5D. York, UK: Centre for Health Economics, University of York; 1999.
   Google Scholar
• Luengo-Fernandez R, Yiin GS, Gray AM, et al. Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke. 2013;8(5):308–314.
   PubMed Web of Science ®Google Scholar
• Gage BC, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156(16):1829–1836.
   PubMed Web of Science ®Google Scholar
• Sekelj S, Sandler B, Johnston E, et al. Detecting undiagnosed atrial fibrillation in UK primary care: validation of a machine learning prediction algorithm in a retrospective cohort study. Eur J Prev Cardiol. 2021;28(6):598–605.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE health technology evaluations: the manual; 2022 [cited 2022 Jan 31]. Available from: http://www.nice.org.uk/process/pmg36
   Google Scholar
• Briggs AH, Schulpher CK. Decision modelling for health economic evaluation. Oxford, UK; Oxford University Press; 2006.
   Google Scholar
• Aronsson M, Svennberg E, Rosenqvist M, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace. 2015;17(7):1023–1029.
   PubMed Web of Science ®Google Scholar
• Svennberg E, Friberg L, Frykman V, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet. 2021;398(10310):1498–1506.
   PubMed Web of Science ®Google Scholar